COSA:NETs guidelines/Short and Long-Acting Somatostatin Analogues (SSA)
|Information on authorship and revision|
|Last reviewed:||November 2010|
|Author(s):||Tim Price (Chair), Yu Jo Chua, Dragan Damianovich, David Goldstein, Winston Liauw, Michael Michael, Bruce Robinson
Short and Long-Acting Somatostatin Analogues (SSA)
The role of SSAs for the amelioration of symptoms of the carcinoid syndrome from functional GEP NETs is well established. The two main groups of agents currently available in Australia, octreotide and lanreotide, have not been directly compared; both are available in short and long acting preparations, but their administration differs. Lanreotide is not available in New Zealand.
Newly reported data also suggests that SSAs have anti-proliferative activity, patients with well-differentiated low proliferative index metastatic midgut NETs, whether symptomatic or asymptomatic, having a significantly longer progression-free survival when treated with octreotide LAR compared to placebo.  These data however have their limitations ; if consistent results are reported by a similar randomised trial based on lanreotide currently being completed, the conclusions from this study would be strengthened. At the present time uncertain issues include whether these results can be generalised to non-midgut or intermediate grade disease, and the optimal timing for commencement of SSA treatment.